These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 19712190)

  • 21. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring biologics for the treatment of psoriasis.
    Papp KA
    Clin Dermatol; 2008; 26(5):515-21. PubMed ID: 18755370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective.
    Jones-Caballero M; Unaeze J; Peñas PF; Stern RS
    Arch Dermatol; 2007 Jul; 143(7):846-50. PubMed ID: 17638727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C; García A; Blasco AJ; Lázaro P
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatments for psoriasis and the risk of malignancy.
    Patel RV; Clark LN; Lebwohl M; Weinberg JM
    J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
    Sobell JM; Hallas SJ
    Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy).
    Sánchez-Regaña M; Sola-Ortigosa J; Alsina-Gibert M; Vidal-Fernández M; Umbert-Millet P
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):579-86. PubMed ID: 21198950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with biologics for psoriasis in daily practice: switching is worth a try.
    Lecluse LL; de Groot M; Bos JD; Spuls PI
    Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
    [No Abstract]   [Full Text] [Related]  

  • 31. Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
    Smith EC; Riddle C; Menter MA; Lebwohl M
    Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence.
    Foley PA; Quirk C; Sullivan JR; Dolianitis C; Hack SP; Thirunavukkarasu K; Cooper AJ
    J Eur Acad Dermatol Venereol; 2010 Oct; 24(10):1135-43. PubMed ID: 20337816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of moderate-to-severe plaque psoriasis.
    Salgo R; Thaçi D
    G Ital Dermatol Venereol; 2009 Dec; 144(6):701-11. PubMed ID: 19907408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining the new biologic agents with our current psoriasis armamentarium.
    Lebwohl M
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S118-24. PubMed ID: 12894135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
    Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D;
    Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative tolerability of systemic treatments for plaque-type psoriasis.
    McClure SL; Valentine J; Gordon KB
    Drug Saf; 2002; 25(13):913-27. PubMed ID: 12381213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with the systemic treatment of severe forms of psoriasis.
    Tichý M; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Mar; 156(1):29-40. PubMed ID: 22580858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of biologic treatments for psoriasis with emphasis on infliximab.
    Pirzada S; Tomi Z; Gulliver W
    Skin Therapy Lett; 2007 Apr; 12(3):1-4. PubMed ID: 17487347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review.
    Shuja F; Chan CS; Rosen T
    Dermatol Clin; 2010 Jul; 28(3):511-21, 523-4; quiz 522-3. PubMed ID: 20510761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.